A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Phase 1 Completed 38 enrolled AbbVie

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.

Timeline

Start: 2023-06-30
Primary completion: 2025-02-21
Completion: 2025-02-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Emraclidine	Small molecule	10 mg	Oral

Indications

No indication recorded.